UCB SA engages in the research, development, and commercialization of pharmaceutical and biotechnology products. It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec. The company was founded by Emmanuel Janssen on January 18, 1928 and is headquartered in Brussels, Belgium.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone32-2559-9999
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$4.55 billion
Profitability
Miscellaneous
Employees6,828
Next Earnings DateN/A
OptionableNot Optionable
UCB (OTCMKTS:UCBJF) Frequently Asked Questions
What is UCB's stock symbol?
UCB trades on the OTCMKTS under the ticker symbol "UCBJF."
What is the consensus analysts' recommendation for UCB?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for UCB in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for UCB.
Has UCB been receiving favorable news coverage?
Media coverage about UCBJF stock has been trending somewhat negative this week, according to InfoTrie. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. UCB earned a news sentiment score of -1.0 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the next few days.
Who are some of UCB's key competitors?
Some companies that are related to UCB include Advanced Accelerator Application (AAAP), Aeolus Pharmaceuticals (AOLS), Affymax (AFFY), American Oriental Bioengineering (AOBI), Aoxing Pharmaceutical (AOXG), Aralez Pharmaceuticals (ARLZ), ARMO Biosciences (ARMO), Bohai Pharmaceuticals Group (BOPH), Cardiome Pharma (CRME), Concordia International (CXRXD), Concordia International (CXRX), Depomed (DEPO), Egalet (EGLT), Eleven Biotherapeutics (EBIO) and Epirus Biopharmaceuticals (EPRSQ).
What other stocks do shareholders of UCB own?
Who are UCB's key executives?
UCB's management team includes the folowing people:
- Jean-Christophe Tellier, Chief Executive Officer & Executive Director
- Charl van Zyl, Chief Operating Officer
- Detlef Thielgen, Chief Financial Officer & Executive Vice President
- Iris Löw-Friedrich, Chief Medical Officer & Executive Vice President
- Dhavalkumar Patel, Chief Scientific Officer & EVP
How do I buy shares of UCB?
Shares of UCBJF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is UCB's stock price today?
One share of UCBJF stock can currently be purchased for approximately $77.95.
What is UCB's official website?
How can I contact UCB?
UCB's mailing address is 60 ALLEE DE LA RECHERCHE, BRUSSELS C9, 1070. The company can be reached via phone at 32-2559-9999 or via email at [email protected]
MarketBeat Community Rating for UCB (OTCMKTS UCBJF)
MarketBeat's community ratings are surveys of what our community members think about UCB and other stocks. Vote "Outperform" if you believe UCBJF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe UCBJF will underperform the S&P 500 over the long term. You may vote once every thirty days.
